-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, April 20, April 15, NMPA official website data shows that Hunan Qianjin Xiangjiang Pharmaceutical's application for the 4 types of imitation of Apixaban tablets was approved and deemed to have been reviewed.
Earlier, the product was approved and deemed to be the same.
11 companies have passed the evaluation.
Apixaban tablets were included in the third batch of national sourcing companies.
After the original research drug company lost the bid, whether it will fully attack the retail market has attracted the attention of the industry.
Earlier, the product was approved and deemed to be the same.
11 companies have passed the evaluation.
Apixaban tablets were included in the third batch of national sourcing companies.
After the original research drug company lost the bid, whether it will fully attack the retail market has attracted the attention of the industry.
Figure 1: The corporate competitive landscape of apixaban tablets in 2020H1
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Apixaban is a highly selective direct factor Xa inhibitor.
It is a new type of oral anticoagulant.
It is mainly used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism.
Before 2018, Bristol-Myers Squibb monopolized the market, especially after entering the national medical insurance catalogue, sales grew rapidly.
In 2019, domestic high-end generic drugs joined the battle, and Hausen, Zhengda Tianqing Pharmaceutical Group and Kelun became the first batch of pioneers.
In one year, in the first half of 2020, Chia Tai Tianqing Pharmaceutical Group has become the market leader of this product.
Hausen follows closely but the potential is promising.
Kelun has been approved for a short time to market, and there is still the possibility of a major outbreak.
It is a new type of oral anticoagulant.
It is mainly used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism.
Before 2018, Bristol-Myers Squibb monopolized the market, especially after entering the national medical insurance catalogue, sales grew rapidly.
In 2019, domestic high-end generic drugs joined the battle, and Hausen, Zhengda Tianqing Pharmaceutical Group and Kelun became the first batch of pioneers.
In one year, in the first half of 2020, Chia Tai Tianqing Pharmaceutical Group has become the market leader of this product.
Hausen follows closely but the potential is promising.
Kelun has been approved for a short time to market, and there is still the possibility of a major outbreak.
In the third batch of national procurement bids, four domestic pharmaceutical companies won the bids.
Currently, the market is led by Chia Tai Tianqing Pharmaceutical Group and Hausen.
Under the attack of new entrants Qilu and Jiangsu Jiayi Pharmaceutical , only the original pharmaceutical companies are left.
Twenty percent of the market share will also continue to be compressed.
Currently, the market is led by Chia Tai Tianqing Pharmaceutical Group and Hausen.
Under the attack of new entrants Qilu and Jiangsu Jiayi Pharmaceutical , only the original pharmaceutical companies are left.
Twenty percent of the market share will also continue to be compressed.
Figure 2: Sales of Apixaban in the retail market
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In the physical pharmacies of Chinese cities , the sales scale of apixaban tablets has not yet increased, but the market potential is promising.
In 2020, the sales are expected to exceed 20 million yuan, and the overall growth rate is more than 195%.
From the perspective of enterprises , Hausen and Chia Tai Tianqing Pharmaceutical Group are expected to grow at 182.
20% and 286.
42% in 2020, while the original research pharmaceutical company Squibb also has 154.
95%.
In 2020, the sales are expected to exceed 20 million yuan, and the overall growth rate is more than 195%.
From the perspective of enterprises , Hausen and Chia Tai Tianqing Pharmaceutical Group are expected to grow at 182.
20% and 286.
42% in 2020, while the original research pharmaceutical company Squibb also has 154.
95%.
At present, the retail market is very friendly to the domestic pharmaceutical industry and the original research pharmaceutical companies.
This time Hunan Qianjin Xiangjiang Pharmaceutical won the approval, whether it will first deploy the retail market, it needs to be verified by the market.
This time Hunan Qianjin Xiangjiang Pharmaceutical won the approval, whether it will first deploy the retail market, it needs to be verified by the market.
Source: NMPA official website, Minet database
Medical Network, April 20, April 15, NMPA official website data shows that Hunan Qianjin Xiangjiang Pharmaceutical's application for the 4 types of imitation of Apixaban tablets was approved and deemed to have been reviewed.
Earlier, the product was approved and deemed to be the same.
11 companies have passed the evaluation.
Apixaban tablets were included in the third batch of national sourcing companies.
After the original research drug company lost the bid, whether it will fully attack the retail market has attracted the attention of the industry.
Earlier, the product was approved and deemed to be the same.
11 companies have passed the evaluation.
Apixaban tablets were included in the third batch of national sourcing companies.
After the original research drug company lost the bid, whether it will fully attack the retail market has attracted the attention of the industry.
Figure 1: The corporate competitive landscape of apixaban tablets in 2020H1
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Apixaban is a highly selective direct factor Xa inhibitor.
It is a new type of oral anticoagulant.
It is mainly used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism.
Before 2018, Bristol-Myers Squibb monopolized the market, especially after entering the national medical insurance catalogue, sales grew rapidly.
In 2019, domestic high-end generic drugs joined the battle, and Hausen, Zhengda Tianqing Pharmaceutical Group and Kelun became the first batch of pioneers.
In one year, in the first half of 2020, Chia Tai Tianqing Pharmaceutical Group has become the market leader of this product.
Hausen follows closely but the potential is promising.
Kelun has been approved for a short time to market, and there is still the possibility of a major outbreak.
It is a new type of oral anticoagulant.
It is mainly used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism.
Before 2018, Bristol-Myers Squibb monopolized the market, especially after entering the national medical insurance catalogue, sales grew rapidly.
In 2019, domestic high-end generic drugs joined the battle, and Hausen, Zhengda Tianqing Pharmaceutical Group and Kelun became the first batch of pioneers.
In one year, in the first half of 2020, Chia Tai Tianqing Pharmaceutical Group has become the market leader of this product.
Hausen follows closely but the potential is promising.
Kelun has been approved for a short time to market, and there is still the possibility of a major outbreak.
In the third batch of national procurement bids, four domestic pharmaceutical companies won the bids.
Currently, the market is led by Chia Tai Tianqing Pharmaceutical Group and Hausen.
Under the attack of new entrants Qilu and Jiangsu Jiayi Pharmaceutical , only the original pharmaceutical companies are left.
Twenty percent of the market share will also continue to be compressed.
Currently, the market is led by Chia Tai Tianqing Pharmaceutical Group and Hausen.
Under the attack of new entrants Qilu and Jiangsu Jiayi Pharmaceutical , only the original pharmaceutical companies are left.
Twenty percent of the market share will also continue to be compressed.
Figure 2: Sales of Apixaban in the retail market
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In the physical pharmacies of Chinese cities , the sales scale of apixaban tablets has not yet increased, but the market potential is promising.
In 2020, the sales are expected to exceed 20 million yuan, and the overall growth rate is more than 195%.
From the perspective of enterprises , Hausen and Chia Tai Tianqing Pharmaceutical Group are expected to grow at 182.
20% and 286.
42% in 2020, while the original research pharmaceutical company Squibb also has 154.
95%.
In 2020, the sales are expected to exceed 20 million yuan, and the overall growth rate is more than 195%.
From the perspective of enterprises , Hausen and Chia Tai Tianqing Pharmaceutical Group are expected to grow at 182.
20% and 286.
42% in 2020, while the original research pharmaceutical company Squibb also has 154.
95%.
At present, the retail market is very friendly to the domestic pharmaceutical industry and the original research pharmaceutical companies.
This time Hunan Qianjin Xiangjiang Pharmaceutical won the approval, whether it will first deploy the retail market, it needs to be verified by the market.
This time Hunan Qianjin Xiangjiang Pharmaceutical won the approval, whether it will first deploy the retail market, it needs to be verified by the market.
Source: NMPA official website, Minet database
Medical Network, April 20, April 15, NMPA official website data shows that Hunan Qianjin Xiangjiang Pharmaceutical's application for the 4 types of imitation of Apixaban tablets was approved and deemed to have been reviewed.
Earlier, the product was approved and deemed to be the same.
11 companies have passed the evaluation.
Apixaban tablets were included in the third batch of national sourcing companies.
After the original research drug company lost the bid, whether it will fully attack the retail market has attracted the attention of the industry.
Earlier, the product was approved and deemed to be the same.
11 companies have passed the evaluation.
Apixaban tablets were included in the third batch of national sourcing companies.
After the original research drug company lost the bid, whether it will fully attack the retail market has attracted the attention of the industry.
Figure 1: The corporate competitive landscape of apixaban tablets in 2020H1
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Apixaban is a highly selective direct factor Xa inhibitor.
It is a new type of oral anticoagulant.
It is mainly used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism.
Before 2018, Bristol-Myers Squibb monopolized the market, especially after entering the national medical insurance catalogue, sales grew rapidly.
In 2019, domestic high-end generic drugs joined the battle, and Hausen, Zhengda Tianqing Pharmaceutical Group and Kelun became the first batch of pioneers.
In one year, in the first half of 2020, Chia Tai Tianqing Pharmaceutical Group has become the market leader of this product.
Hausen follows closely but the potential is promising.
Kelun has been approved for a short time to market, and there is still the possibility of a major outbreak.
It is a new type of oral anticoagulant.
It is mainly used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism.
Before 2018, Bristol-Myers Squibb monopolized the market, especially after entering the national medical insurance catalogue, sales grew rapidly.
In 2019, domestic high-end generic drugs joined the battle, and Hausen, Zhengda Tianqing Pharmaceutical Group and Kelun became the first batch of pioneers.
In one year, in the first half of 2020, Chia Tai Tianqing Pharmaceutical Group has become the market leader of this product.
Hausen follows closely but the potential is promising.
Kelun has been approved for a short time to market, and there is still the possibility of a major outbreak.
In the third batch of national procurement bids, four domestic pharmaceutical companies won the bids.
Currently, the market is led by Chia Tai Tianqing Pharmaceutical Group and Hausen.
Under the attack of new entrants Qilu and Jiangsu Jiayi Pharmaceutical , only the original pharmaceutical companies are left.
Twenty percent of the market share will also continue to be compressed.
Medicine Medicine MedicineCurrently, the market is led by Chia Tai Tianqing Pharmaceutical Group and Hausen.
Under the attack of new entrants Qilu and Jiangsu Jiayi Pharmaceutical , only the original pharmaceutical companies are left.
Twenty percent of the market share will also continue to be compressed.
Figure 2: Sales of Apixaban in the retail market
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In the physical pharmacies of Chinese cities , the sales scale of apixaban tablets has not yet increased, but the market potential is promising.
In 2020, the sales are expected to exceed 20 million yuan, and the overall growth rate is more than 195%.
From the perspective of enterprises , Hausen and Chia Tai Tianqing Pharmaceutical Group are expected to grow at 182.
20% and 286.
42% in 2020, while the original research pharmaceutical company Squibb also has 154.
95%.
Pharmacy pharmacy pharmacy enterprise enterprise enterpriseIn 2020, the sales are expected to exceed 20 million yuan, and the overall growth rate is more than 195%.
From the perspective of enterprises , Hausen and Chia Tai Tianqing Pharmaceutical Group are expected to grow at 182.
20% and 286.
42% in 2020, while the original research pharmaceutical company Squibb also has 154.
95%.
At present, the retail market is very friendly to the domestic pharmaceutical industry and the original research pharmaceutical companies.
This time Hunan Qianjin Xiangjiang Pharmaceutical won the approval, whether it will first deploy the retail market, it needs to be verified by the market.
This time Hunan Qianjin Xiangjiang Pharmaceutical won the approval, whether it will first deploy the retail market, it needs to be verified by the market.
Source: NMPA official website, Minet database
